NASDAQ · IXHL
Incannex Healthcare Limited
$2.58-$0.13 (-4.8%)
Incannex Healthcare Limited’s quoted price sits in the lower half of its reported 52-week range, 82.7% below the high.
Loading market information…
ASX · MXC.AX · AUD
Stock price, earnings
Quote as of Apr 2, 2024, 05:10 AM UTC. Cached market data; not a live quote.
One-year closing-price history · AUD. Historical prices are not a forecast.
MGC Pharmaceuticals Limited’s quoted price sits in the lower half of its reported 52-week range, 96.18% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow MGC Pharmaceuticals Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
MGC Pharmaceuticals Limited, an Australian biopharmaceutical firm established in West Perth in 2014, focuses on the worldwide development and distribution of plant-derived medicines. Its product portfolio encompasses both medicinal cannabis solutions and other botanical therapeutics. The company's key investigational treatments include CimetrA, currently in Phase III clinical trials for the symptomatic relief of early-stage COVID-19; CannEpil, a cannabis-based therapy undergoing Phase IIb studies for drug-resistant epilepsy; and CogniCann, which is in Phase II clinical development for alleviating dementia symptoms. Beyond these core candidates, MGC Pharmaceuticals also supplies the ArtemiC range, various other cannabinoid-infused products, and non-pharmaceutical items. Additionally, the company provides expert consulting services, particularly in clinical research. The company was previously named Erin Resources Limited before adopting its current identity, MGC Pharmaceuticals Limited, in December 2015.
Latest available per-share figures in AUD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:46 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$2.58-$0.13 (-4.8%)
Incannex Healthcare Limited’s quoted price sits in the lower half of its reported 52-week range, 82.7% below the high.
A$0.01A$0.00 (0.0%)
Creso Pharma Limited’s quoted price sits in the lower half of its reported 52-week range, 83.02% below the high.
A$0.03+A$0.00 (+3.7%)
Pharmaxis Ltd’s quoted price sits in the lower half of its reported 52-week range, 56.92% below the high.
$8.72+$0.39 (+4.68%)
Kazia Therapeutics Ltd ADR’s quoted price sits in the lower half of its reported 52-week range, 49.89% below the high.
A$0.04A$0.00 (0.0%)
CardieX Limited’s quoted price sits in the lower half of its reported 52-week range, 79.43% below the high.
A$0.04A$0.00 (0.0%)
AusCann Group Holdings Ltd’s quoted price sits in the lower half of its reported 52-week range, 4.76% below the high.
A$0.01+A$0.00 (+22.22%)
1st Group Limited’s quoted price sits in the upper half of its reported 52-week range, 26.67% below the high.
A$6.60A$0.00 (0.0%)
Medlab Clinical Limited: Healthcare · Biotechnology.
